title: Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis.
abstract: Thrombosis of hemodialysis vascular access grafts represents a major medical and economic burden. Experimental and clinical models suggest a role for antiplatelet agents in the prevention of thrombosis. The study was designed to determine the efficacy of the combination of aspirin and clopidogrel in the prevention of graft thrombosis. The study was a randomized, double-blind trial conducted at 30 hemodialysis units at Veterans Affairs medical centers. Participants undergoing hemodialysis with a polytetrafluoroethylene graft in the arm were randomized to receive either double placebos or aspirin (325 mg) and clopidogrel (75 mg) daily. Participants were to be monitored while receiving study medications for a minimum of 2 yr. The study was stopped after randomization of 200 participants, as recommended by the Data Safety and Monitoring Board because of a significantly increased risk of bleeding among the participants receiving aspirin and clopidogrel therapy. The cumulative incidence of bleeding events was significantly greater for those participants, compared with participants receiving placebos [hazard ratio, 1.98; 95% confidence interval (CI), 1.19 to 3.28; P = 0.007]. Twenty-three participants in the placebo group and 44 participants in the active treatment group experienced a bleeding event (P = 0.006). There was no significant benefit of active treatment in the prevention of thrombosis (hazard ratio, 0.81; 95% CI, 0.47 to 1.40; P = 0.45), although there was a trend toward a benefit among participants who had not experienced previous graft thrombosis (hazard ratio, 0.52; 95% CI, 0.22 to 1.26; P = 0.14). In the hemodialysis population, therapy with aspirin and clopidogrel was associated with a significantly increased risk of bleeding and probably would not result in a reduced frequency of graft thrombosis.
authors.affiliation: Department of Veterans Affairs Boston Healthcare System and Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02130, USA. james.kaufman@med.va.gov
authors.forename: James S
authors.initials: JS
authors.lastname: Kaufman
authors.forename: Theresa Z
authors.initials: TZ
authors.lastname: O'Connor
authors.forename: Jane Hongyuan
authors.initials: JH
authors.lastname: Zhang
authors.forename: Robert E
authors.initials: RE
authors.lastname: Cronin
authors.forename: Louis D
authors.initials: LD
authors.lastname: Fiore
authors.forename: Michael B
authors.initials: MB
authors.lastname: Ganz
authors.forename: David S
authors.initials: DS
authors.lastname: Goldfarb
authors.forename: Peter N
authors.initials: PN
authors.lastname: Peduzzi
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage*; D002408:Catheters, Indwelling / Q000009:adverse effects*; D000077144:Clopidogrel; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D011138:Polytetrafluoroethylene / Q000009:adverse effects; D006435:Renal Dialysis; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D013988:Ticlopidine / Q000008:administration & dosage* / Q000031:analogs & derivatives*
chemical_list: D010975:Platelet Aggregation Inhibitors; D011138:Polytetrafluoroethylene; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin